RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells

Gastric Cancer

Volumn 19, Issue 1, 2016, Pages 85-97

  Tamura, Fumito ^a   Sato, Yasushi ^a   Hirakawa, Masahiro ^a   Yoshida, Makoto ^a   Ono, Michihiro ^a   Osuga, Takahiro ^a   Okagawa, Yutaka ^a   Uemura, Naoki ^a   Arihara, Yohei ^a   Murase, Kazuyuki ^a   Kawano, Yutaka ^a   Iyama, Satoshi ^a   Takada, Kohichi ^a   Hayashi, Tsuyoshi ^a   Sato, Tsutomu ^a   Miyanishi, Koji ^a   Kobune, Masayoshi ^a   Takimoto, Rishu ^a   Kato, Junji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric cancer; Peritoneal dissemination; ST6GalNAc I; STAT5b; STn

Indexed keywords

BETA4 INTEGRIN; SIALYL TN ANTIGEN; SMALL INTERFERING RNA; SOMATOMEDIN C; STAT5B PROTEIN; TN ANTIGEN; UNCLASSIFIED DRUG; VIMENTIN; CMP-N-ACETYLNEURAMINATE-ALPHA-N-ACETYLGALACTOSAMINIDE ALPHA-2,6-SIALYLTRANSFERASE; SIALOSYL-TN ANTIGEN; SIALYLTRANSFERASE; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; GASTRIC CANCER CELL LINE; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IGF I GENE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ST6GALNAC I GENE; STOMACH CANCER; TUMOR WEIGHT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; DRUG SCREENING; ENZYMOLOGY; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PERITONEUM TUMOR; SECONDARY; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE SILENCING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE, INBRED BALB C; PERITONEAL NEOPLASMS; RNA INTERFERENCE; SIALYLTRANSFERASES; STAT5 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84951568442     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-014-0454-z     Document Type: Article

References (49)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
4. Takahashi I, Matsusaka T, Onohara T, Nishizaki T, Ishikawa T, Tashiro H, et al. Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology. 2000;47:1485–8.
5. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer (Phila). 2000;88:358–63.
6. Bae JM, Yeo KJ, Kim SW, Kim SW, Song SK. Clinical outcomes according to primary treatment in gastric cancer patients with peritoneal seeding. J Gastric Cancer. 2011;11:167–72.
7. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol. 1996;179:358–69.
8. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J. 1997;14:569–76.
9. Baldus SE, Hanisch FG. Biochemistry and pathological importance of mucin-associated antigens in gastrointestinal neoplasia. Adv Cancer Res. 2000;79:201–48.
10. David L, Nesland JM, Clausen H, Carneiro F, Sobrinho-Simões M. Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases. APMIS Suppl. 1992;27:162–72.
11. Victorzon M, Nordling S, Nilsson O, Roberts PJ, Haglund C. Sialyl Tn antigen is an independent predictor of outcome in patients with gastric cancer. Int J Cancer. 1996;65:295–300.
12. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer (Phila). 1990;66:1960–6.
13. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol. 1992;10:95–101.
14. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. STn and prognosis in breast cancer. Oncology. 2001;61:299–305.
15. Yonezawa S, Tachikawa T, Shin S, Sato E. Sialosyl-Tn antigen. Its distribution in normal human tissues and expression in adenocarcinomas. Am J Clin Pathol. 1992;98:167–74.
16. Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002;123:1052–60.
17. Springer GF. T and Tn, general carcinoma autoantigens. Science. 1984;224:1198–206.
18. Miles DW, Happerfield LC, Smith P, Gillibrand R, Bobrow LG, Gregory WM, et al. Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer. 1994;70:1272–5.
19. Davidson B, Gotlieb WH, Ben-Baruch G, Kopolovic J, Goldberg I, Nesland JM, et al. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases: a clinicopathologic study. Gynecol Oncol. 2000;77:35–43.
20. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1999;1473:67–95.
21. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia. 2002;7:209–21.
22. Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2 → 6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res. 1988;48:2214–20.
23. Yamada T, Watanabe A, Yamada Y, Shino Y, Tanase M, Yamashita J, et al. Sialosyl Tn antigen expression is associated with the prognosis of patients with advanced gastric cancer. Cancer (Phila). 1995;76:1529–36.
24. Werther JL, Rivera-MacMurray S, Bruckner H, Tatematsu M, Itzkowitz SH. Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. Br J Cancer. 1994;69:613–6.
25. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, et al. Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. Anticancer Res. 2002;22:451–8.
26. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989;49:197–204.
27. Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, et al. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front Biosci. 2011;3:1443–55.
28. Julien S, Krzewinski-Recchi MA, Harduin-Lepers A, Gouyer V, Huet G, Le Bourhis X, et al. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J. 2001;18:883–93.
29. Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A, et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 2004;64:7050–7.
30. Ikehara Y, Kojima N, Kurosawa N, Kudo T, Kono M, Nishihara S, et al. Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. Glycobiology. 1999;9:1213–24.
31. Brockhausen I, Yang J, Lehotay M, Ogata S, Itzkowitz S. Pathways of mucin O-glycosylation in normal and malignant rat colonic epithelial cells reveal a mechanism for cancer-associated sialyl-Tn antigen expression. Biol Chem. 2001;382:219–32.
32. Pinho S, Marcos NT, Ferreira B, Carvalho AS, Oliveira MJ, Santos-Silva F, et al. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 2007;249:157–70.
33. Ozaki H, Matsuzaki H, Ando H, Kaji H, Nakanishi H, Ikehara Y, et al. Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin Exp Metastasis. 2012;29:229–38.
34. Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349:1139–47.
35. Woelfle J, Chia DJ, Rotwein P. Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem. 2003;278:51261–6.
36. Chia DJ, Ono M, Woelfle J, Schlesinger-Massart M, Jiang H, Rotwein P. Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription. J Biol Chem. 2006;281:3190–7.
37. Rotwein P. Mapping the growth hormone–Stat5b–IGF-I transcriptional circuit. Trends Endocrinol Metab. 2012;23:186–93.
38. Joung YH, Lee MY, Lim EJ, Kim MS, Hwang TS, Kim SY, et al. Hypoxia activates the IGF-1 expression through STAT5b in human HepG2 cells. Biochem Biophys Res Commun. 2007;358:733–8.
39. Lim EJ, Joung YH, Jung SM, Park SH, Park JH, Kim SY, et al. Hemin inhibits cyclin D1 and IGF-1 expression via STAT5b under hypoxia in ERalpha-negative MDA-MB 231 breast cancer cells. Int J Oncol. 2010;36:1243–51.
40. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006;5:1708–13.
41. Lee DY, Yang DH, Kang CW, Kim SJ, Joo CU, Cho SC, et al. Serum insulin-like growth factors (IGFs) and IGF binding protein (IGFBP)-3 in patients with gastric cancer: IGFBP-3 protease activity induced by surgery. J Korean Med Sci. 1997;12:32–9.
42. Coşkun U, Günel N, Sancak B, Günel U, Onuk E, Bayram O, et al. Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients. Breast. 2003;12:104–10.
43. El-Mesallamy HO, Hamdy NM, Zaghloul AS, Sallam AM. Clinical value of circulating lipocalins and insulin-like growth factor axis in pancreatic cancer diagnosis. Pancreas. 2013;42:149–54.
44. Himpe E, Kooijman R. Insulin-like growth factor-I receptor signal transduction and the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. BioFactors. 2009;35:76–81.
45. Park JH, Darvin P, Lim EJ, Joung YH, Hong DY, Park EU, et al. Hwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenografts. PLoS One. 2012;7:e40531.
46. Lee TK, Man K, Poon RT, Lo CM, Yuen AP, Ng IO, et al. Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res. 2006;66:9948–56.
47. Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, et al. Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res. 2008;14:7682–90.
48. Moser C, Ruemmele P, Gehmert S, Schenk H, Kreutz MP, Mycielska ME, et al. STAT5b as molecular target in pancreatic cancer: inhibition of tumor growth, angiogenesis, and metastases. Neoplasia. 2012;14:915–25.
49. Kim OS, Park EJ, Joe EH, Jou I. JAK-STAT signaling mediates gangliosides-induced inflammatory responses in brain microglial cells. J Biol Chem. 2002;277:40594–601.